DekaBank Deutsche Girozentrale Purchases Shares of 45,000 Novavax, Inc. (NASDAQ:NVAX)

DekaBank Deutsche Girozentrale purchased a new position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 45,000 shares of the biopharmaceutical company's stock, valued at approximately $290,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of NVAX. Deutsche Bank AG boosted its holdings in shares of Novavax by 47.5% during the fourth quarter. Deutsche Bank AG now owns 123,581 shares of the biopharmaceutical company's stock worth $994,000 after acquiring an additional 39,787 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Novavax by 10.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 101,812 shares of the biopharmaceutical company's stock worth $817,000 after acquiring an additional 9,711 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Novavax by 0.4% during the fourth quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company's stock worth $3,509,000 after acquiring an additional 1,664 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Novavax by 28.8% during the fourth quarter. JPMorgan Chase & Co. now owns 76,576 shares of the biopharmaceutical company's stock worth $616,000 after acquiring an additional 17,101 shares during the period. Finally, California State Teachers Retirement System boosted its holdings in shares of Novavax by 12.3% during the fourth quarter. California State Teachers Retirement System now owns 135,486 shares of the biopharmaceutical company's stock worth $1,089,000 after acquiring an additional 14,853 shares during the period. Institutional investors own 53.04% of the company's stock.

Analyst Upgrades and Downgrades

NVAX has been the subject of a number of research analyst reports. Citigroup initiated coverage on Novavax in a report on Tuesday, June 17th. They set a "sell" rating and a $6.00 price objective for the company. JPMorgan Chase & Co. reduced their price target on Novavax from $9.00 to $7.00 and set an "underweight" rating on the stock in a research report on Friday, May 9th. Finally, B. Riley reaffirmed a "buy" rating on shares of Novavax in a report on Monday, May 19th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $17.00.

Novavax Price Performance

NVAX traded down $0.06 during trading on Friday, hitting $6.94. 1,498,708 shares of the stock traded hands, compared to its average volume of 6,153,970. Novavax, Inc. has a twelve month low of $5.01 and a twelve month high of $17.81. The company has a market cap of $1.12 billion, a price-to-earnings ratio of 2.62, a PEG ratio of 0.06 and a beta of 2.69. The business has a 50 day moving average price of $6.86 and a 200 day moving average price of $7.38.

Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 EPS for the quarter, beating the consensus estimate of $0.71 by $2.22. Novavax had a net margin of 38.14% and a negative return on equity of 115.51%. The business had revenue of $666.66 million during the quarter, compared to the consensus estimate of $204.08 million. During the same period in the previous year, the business earned ($1.05) earnings per share. The company's revenue was up 610.3% on a year-over-year basis. On average, equities research analysts predict that Novavax, Inc. will post -1.46 earnings per share for the current year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.